BI Asset Management Fondsmaeglerselskab A S Sells 197,423 Shares of The Cooper Companies, Inc. $COO

BI Asset Management Fondsmaeglerselskab A S decreased its stake in The Cooper Companies, Inc. (NASDAQ:COO) by 95.4% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 9,550 shares of the medical device company’s stock after selling 197,423 shares during the period. BI Asset Management Fondsmaeglerselskab A S’s holdings in Cooper Companies were worth $655,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Envestnet Asset Management Inc. increased its stake in shares of Cooper Companies by 0.5% during the 3rd quarter. Envestnet Asset Management Inc. now owns 647,807 shares of the medical device company’s stock worth $44,414,000 after purchasing an additional 3,238 shares during the last quarter. Callan Family Office LLC increased its position in Cooper Companies by 11.9% in the third quarter. Callan Family Office LLC now owns 4,883 shares of the medical device company’s stock worth $335,000 after buying an additional 518 shares during the last quarter. Atlantic Union Bankshares Corp bought a new stake in shares of Cooper Companies in the third quarter valued at $151,000. Arizona State Retirement System grew its stake in Cooper Companies by 1.1% in the 3rd quarter. Arizona State Retirement System now owns 59,059 shares of the medical device company’s stock valued at $4,049,000 after buying an additional 641 shares in the last quarter. Finally, Ruffer LLP raised its holdings in Cooper Companies by 444.2% during the 3rd quarter. Ruffer LLP now owns 1,347,850 shares of the medical device company’s stock valued at $92,407,000 after acquiring an additional 1,100,188 shares during the period. 24.39% of the stock is currently owned by hedge funds and other institutional investors.

Cooper Companies Trading Down 0.8%

Shares of COO opened at $81.48 on Tuesday. The firm’s 50 day simple moving average is $81.45 and its 200 day simple moving average is $74.59. The company has a market capitalization of $15.97 billion, a P/E ratio of 43.34, a P/E/G ratio of 2.34 and a beta of 1.03. The company has a debt-to-equity ratio of 0.30, a current ratio of 1.89 and a quick ratio of 1.13. The Cooper Companies, Inc. has a 1-year low of $61.78 and a 1-year high of $94.33.

Cooper Companies (NASDAQ:COO) last released its quarterly earnings results on Thursday, December 4th. The medical device company reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $1.11 by $0.04. Cooper Companies had a net margin of 9.16% and a return on equity of 10.02%. The business had revenue of $1.07 billion during the quarter, compared to analysts’ expectations of $1.06 billion. During the same quarter in the previous year, the company earned $1.04 EPS. The business’s quarterly revenue was up 4.6% compared to the same quarter last year. Cooper Companies has set its FY 2026 guidance at 4.450-4.600 EPS and its Q1 2026 guidance at 1.020-1.040 EPS. Sell-side analysts forecast that The Cooper Companies, Inc. will post 3.98 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the company. William Blair upgraded Cooper Companies to a “strong-buy” rating in a research report on Friday, January 30th. Barclays set a $98.00 price target on Cooper Companies and gave the company an “overweight” rating in a research report on Monday, January 26th. Wells Fargo & Company raised their price objective on shares of Cooper Companies from $72.00 to $82.00 and gave the company an “equal weight” rating in a research report on Friday, December 5th. Morgan Stanley boosted their price objective on shares of Cooper Companies from $76.00 to $83.00 and gave the company an “equal weight” rating in a research note on Monday, December 8th. Finally, Weiss Ratings upgraded shares of Cooper Companies from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, January 12th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $90.77.

Insider Activity at Cooper Companies

In other Cooper Companies news, Director Lawrence Erik Kurzius purchased 2,000 shares of the firm’s stock in a transaction on Wednesday, December 17th. The shares were purchased at an average cost of $82.50 per share, with a total value of $165,000.00. Following the completion of the purchase, the director owned 7,777 shares of the company’s stock, valued at $641,602.50. The trade was a 34.62% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Holly R. Sheffield purchased 1,230 shares of the business’s stock in a transaction on Tuesday, December 16th. The shares were acquired at an average price of $80.75 per share, with a total value of $99,322.50. Following the completion of the transaction, the insider owned 39,052 shares of the company’s stock, valued at approximately $3,153,449. This trade represents a 3.25% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders bought a total of 16,014 shares of company stock worth $1,304,416 in the last quarter. 1.98% of the stock is owned by company insiders.

Cooper Companies Profile

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.